Q1 Earnings Estimate for CELZ Issued By Roth Capital

Posted by Defense World Staff on Nov 17th, 2024

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ – Free Report) – Stock analysts at Roth Capital issued their Q1 2025 earnings per share (EPS) estimates for shares of Creative Medical Technology in a report issued on Wednesday, November 13th. Roth Capital analyst J. Aschoff forecasts that the company will earn ($0.64) per share for the quarter. The consensus estimate for Creative Medical Technology’s current full-year earnings is ($3.29) per share. Roth Capital also issued estimates for Creative Medical Technology’s Q2 2025 earnings at ($0.54) EPS, Q3 2025 earnings at ($0.54) EPS and Q4 2025 earnings at ($0.54) EPS.

Creative Medical Technology Price Performance

Creative Medical Technology stock opened at $2.70 on Friday. The business has a 50 day moving average of $3.46 and a 200-day moving average of $3.69. Creative Medical Technology has a 1 year low of $2.52 and a 1 year high of $10.28. The company has a market capitalization of $4.73 million, a P/E ratio of -0.71 and a beta of 2.01.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Creative Medical Technology stock. Aaron Wealth Advisors LLC boosted its stake in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ – Free Report) by 19.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,570 shares of the company’s stock after acquiring an additional 3,170 shares during the period. Aaron Wealth Advisors LLC owned 1.45% of Creative Medical Technology worth $75,000 at the end of the most recent quarter. Institutional investors and hedge funds own 1.42% of the company’s stock.

Creative Medical Technology Company Profile

(Get Free Report)

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.